title: TAVI: New trials and registries offer further welcome evidence - U.S. CoreValve, CHOICE, and GARY.
abstract: The introduction of transcatheter aortic valve implantation (TAVI) has resulted in a paradigm shift in the treatment of patients with severe aortic stenosis. Data from the recent U.S CoreValve Trial suggest, for the first time, that TAVI is associated with a significantly higher rate of survival at one year compared to surgical aortic valve replacement (SAVR) in the treatment of high-risk patients affected by severe aortic stenosis. The present review discusses this study and the current evidence about TAVI, for the treatment of severe aortic stenosis, from major trials and real world registries.
authors: NIHR Biomedical Research Unit Royal Brompton Hospital, London, United Kingdom.
authors: Michele
authors: M
authors: Pighi
authors: NIHR Biomedical Research Unit Royal Brompton Hospital, London, United Kingdom.
authors: Roberta
authors: R
authors: Serdoz
authors: NIHR Biomedical Research Unit Royal Brompton Hospital, London, United Kingdom.
authors: Ismail Dogu
authors: ID
authors: Kilic
authors: NIHR Biomedical Research Unit Royal Brompton Hospital, London, United Kingdom.
authors: Sara Abou
authors: SA
authors: Sherif
authors: NIHR Biomedical Research Unit Royal Brompton Hospital, London, United Kingdom.
authors: Alistair
authors: A
authors: Lindsay
authors: NIHR Biomedical Research Unit Royal Brompton Hospital, London, United Kingdom.
authors: Carlo
authors: C
authors: Di Mario
keywords: U.S. CoreValve Trial; degenerative aortic valve stenosis; surgical aortic valve replacement; transcatheter aortic valve implantation